These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


75 related items for PubMed ID: 22483568

  • 1. Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
    Namazi H.
    J Crohns Colitis; 2012 Jul; 6(6):734. PubMed ID: 22483568
    [No Abstract] [Full Text] [Related]

  • 2. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 3. What is the role for bisphosphonates in IBD?
    Bernstein CN, Targownik LE, Leslie WD.
    Gut; 2014 Sep; 63(9):1369-70. PubMed ID: 24221457
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 5. The role of risedronate in osteopenia in Crohn's disease.
    Buchan A, Manuel A.
    Gut; 2015 Jan; 64(1):185. PubMed ID: 24304669
    [No Abstract] [Full Text] [Related]

  • 6. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
    van Bodegraven AA, Witte BI, Lips P, Crohn and Bone Study Group of the Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2015 Jan; 64(1):185-6. PubMed ID: 24569060
    [No Abstract] [Full Text] [Related]

  • 7. [Osteoporosis treatment: choices and options].
    Reginster JY.
    Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

  • 9. Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine.
    Benlidayi IC, Ortac EA, Kozanoglu E.
    Acta Clin Belg; 2015 Apr; 70(2):130-2. PubMed ID: 25338093
    [Abstract] [Full Text] [Related]

  • 10. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
    Uyar Y, Baytur Y, Inceboz U, Demir BC, Gumuser G, Ozbilgin K.
    Maturitas; 2009 Jul 20; 63(3):261-7. PubMed ID: 19386450
    [Abstract] [Full Text] [Related]

  • 11. Risedronate.
    Goa KL, Balfour JA.
    Drugs Aging; 1998 Jul 20; 13(1):83-91; discussion 92. PubMed ID: 9679211
    [Abstract] [Full Text] [Related]

  • 12. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
    Matsumoto T, Nagase Y, Iwasawa M, Yasui T, Masuda H, Kadono Y, Nakamura K, Tanaka S.
    Arthritis Rheum; 2011 Dec 20; 63(12):3908-17. PubMed ID: 21898348
    [Abstract] [Full Text] [Related]

  • 13. Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study.
    Okamoto K, Inaba M, Furumitsu Y, Ban A, Mori N, Yukioka K, Imanishi Y, Nishizawa Y.
    Life Sci; 2010 Dec 18; 87(23-26):686-91. PubMed ID: 20951147
    [Abstract] [Full Text] [Related]

  • 14. Effect of risedronate on bone in renal transplant recipients.
    Coco M, Pullman J, Cohen HW, Lee S, Shapiro C, Solorzano C, Greenstein S, Glicklich D.
    J Am Soc Nephrol; 2012 Aug 18; 23(8):1426-37. PubMed ID: 22797188
    [Abstract] [Full Text] [Related]

  • 15. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
    Izumi K, Mizokami A, Sugimoto K, Narimoto K, Kitagawa Y, Koh E, Namiki M.
    Prostate Cancer Prostatic Dis; 2011 Sep 18; 14(3):238-42. PubMed ID: 21423267
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
    Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group.
    J Bone Miner Metab; 2006 Sep 18; 24(5):405-13. PubMed ID: 16937274
    [Abstract] [Full Text] [Related]

  • 17. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubí S, Oppenheimer F.
    Transpl Int; 2007 Aug 18; 20(8):708-11. PubMed ID: 17555530
    [Abstract] [Full Text] [Related]

  • 18. Osteoporosis in men.
    Lems WF, Geusens PP.
    N Engl J Med; 2008 Aug 21; 359(8):868; author reply 869. PubMed ID: 18724402
    [No Abstract] [Full Text] [Related]

  • 19. Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.
    Libouban H, Blouin S, Moreau MF, Baslé MF, Audran M, Chappard D.
    Micron; 2008 Oct 21; 39(7):998-1007. PubMed ID: 18023586
    [Abstract] [Full Text] [Related]

  • 20. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
    Cohran V, Cassedy A, Hawkins A, Bean J, Heubi J.
    J Pediatr Rehabil Med; 2013 Oct 21; 6(2):85-93. PubMed ID: 23803341
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 4.